Treatment of acute bacterial skin and skin structure infections (ABSSSI) places a significant burden on the healthcare system, primarily due to expenditures associated with hospitalization costs. This publication details the results of a budget impact model study designed to estimate the potential annual budget impact of introducing omadacycline as a treatment option for patients with ABSSSI who present to the emergency department for care.
Improving the quality and safety of care in the inpatient and ambulatory settings is, indeed, a global quest. As part of this journey, I had the privilege of traveling to Kuala Lumpur, Malaysia, for the 35th Annual Meeting of the International Society for Quality in Health Care, known as ISQua.
The Medicaid Drug Utilization Review (DUR) program conducted by Medicaid state agencies promotes patient safety through state-administered drug utilization management tools and systems in a 2-phase process.
Collaborative drug therapy management protocols are defined and written agreements between pharmacists and providers that allow pharmacists to optimize medication therapy management for individual patients.
Collaborative Efforts Help the Avoidance of Diabetes Mismanagement
Cost-effectiveness studies of pharmaceutical agents that will soon be released to the market are an important tool that payers and health plans can use when making decisions on coverage, formulary positioning, and budgets.
Over the past several years, many healthcare trends have been identified as micro rather than macro as incremental year-to-year changes dominated the US healthcare market.
Rheumatoid arthritis (RA) is a chronic systemic inflammatory condition that negatively affects the physical and mental health of individuals.
Comorbidities in Rheumatoid Arthritis Present Clinical, Economic Challenges for All Stakeholders
The 2018 midterm elections are a few months behind us, with the Democrats now in control of the House of Representatives and the Republicans maintaining their hold on the Senate. Hence, the future of the pharmaceutical industry—at least until the 2020 presidential election—is unclear.
On February 12, 2019, the US Food and Drug Administration (FDA) granted approval for daratumumab (Darzalex; Janssen), a CD38-directed antibody, to be given in a split-dosing regimen to patients with multiple myeloma (MM). Darzalex is the first and only CD38-directed antibody to receive regulatory approval for the treatment of patients with MM and is the first to be approved for the split-dosing regimen. This new regimen gives patients and healthcare providers the option to split the first dose of Darzalex over the course of 2 consecutive days, which has the benefit of shortening the duration of the first infusion.
  • FDA Resumes Operations After Government Shutdown End
  • FDA Approves New Drug Indication for Use in Hepatocellular Carcinoma
  • FDA Approves Pembrolizumab for Merkel-Cell Carcinoma
Page 8 of 194
Results 71 - 80 of 1934
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME